Positive results mark the first time an immune checkpoint inhibitor-based combination has demonstrated superior efficacy versus chemotherapy as neoadjuvant therapy in a Phase 3 trial in resectable non ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window At the recent ...

PRINCETON, N.J., February 19, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated ...

CheckMate -816 is a Phase 3 randomized, open label, multi-center trial evaluating Opdivo in combination with chemotherapy compared to chemotherapy alone as neoadjuvant treatment in patients with ...

Please provide your email address to receive an email when new articles are posted on . In this video, Sonam Puri, MD, discusses the surgical outcomes from the phase 3 CheckMate 816 trial presented at ...

Conclusions: In CheckMate 816, neoadjuvant NIVO + chemo did not impede the feasibility and timing of surgery, nor the extent or completeness of resection vs chemo alone; treatment was tolerable and ...

Neoadjuvant Opdivo with chemotherapy significantly improves overall survival in resectable NSCLC compared to chemotherapy alone, as shown in the CheckMate-816 study. The study's primary endpoints, ...

Patients with non-small cell lung cancer saw a reduction in their risk of recurrence or death after surgery when treated with pre- and postsurgical Opdivo. For patients with resectable (removable by ...

CheckMate -816 is a Phase 3 randomized, open label, multi-center trial evaluating Opdivo with chemotherapy compared to chemotherapy alone as neoadjuvant treatment in patients with resectable stage IB ...

Please provide your email address to receive an email when new articles are posted on . Nathan A. Pennell, MD, PhD, spoke with Healio about phase 3 findings from the CheckMate 816 trial presented at ...